This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Today's Health Winners and Losers

Shares of NitroMed (NTMD) were among the worst-performing health-related stocks Tuesday, plunging 32% after the drugmaker posted disappointing first-quarter results.

The company reported a loss of $25.9 million, or 75 cents a share, on revenue of $2.3 million. Analysts polled by Thomson First Call expected a smaller loss of 68 cents a share on revenue of $5 million. A year earlier, the company reported a loss of $19.6 million, or 65 cents a share, on revenue of $398,000.

Looking ahead, NitroMed sees 2006 product sales of about $20 million. Analysts project sales of $44.4 million. Shares were trading down $2.75 to $5.86.

Vical (VICL - Get Report) soared 31% after the company reported a better-than-expected first quarter and gave positive early-stage study results of a bird flu vaccine. For the first quarter, the drug developer reported a loss of $4.5 million, or 16 cents a share, on revenue of $5.6 million. Analysts expected a wider loss of 22 cents a share, with revenue of $3.7 million. Last year, the company posted a first-quarter loss of $7.6 million, or 32 cents a share, on revenue of $2.7 million. For 2006, Vical continues to forecast an adjusted loss of $22 million to $26 million.

Separately, the company said its three-component flu vaccine candidate provided 100% protection in mice and ferrets against lethal doses of the H5N1 avian flu virus. Mice and ferrets that did not receive the vaccine did not survive. "Based on the results, the company is continuing to advance toward human testing of the pandemic flu DNA vaccine candidate," Vical said. Shares recently had jumped $1.68 to $7.18.

Shares of ev3 (EVVV) slid 10% after the medical-device company posted mixed first-quarter results and lowered its 2006 sales guidance. The company posted a loss of $24.5 million, or 44 cents a share, narrowed from $28.1 million, or $10.76 a share, a year earlier, when there were far fewer shares outstanding. Excluding items, the company reported a loss of $17.1 million, or 31 cents a share, a penny better than Wall Street's projection. Revenue rose to $42.2 million from $27.7 million, but missed analysts' expectation of $43.5 million.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CYBX $62.89 0.00%
UNH $118.69 0.00%
VICL $1.00 0.00%
UTHR $186.69 0.00%
AAPL $130.28 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs